Rocket Pharmaceuticals
RCKT
78 hedge funds and large institutions have $207M invested in Rocket Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 16 reducing their positions, and 5 closing their positions.
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
81% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 16
41% more capital invested
Capital invested by funds: $147M → $207M (+$59.9M)
18% more funds holding
Funds holding: 66 → 78 (+12)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
89% less call options, than puts
Call options by funds: $447K | Put options by funds: $4.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$3.6M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.87M |
| 3 |
Millennium Management
New York
|
+$1.73M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.66M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$437K |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$351K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$263K |
| 4 |
SAM
Senzar Asset Management
New York
|
-$247K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$195K |
RCKT Hedge Fund Activity: Q3 2016 in Review
78 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2016, worth a combined $207M — up 41% from $147M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new RCKT positions and 5 closed out — a net gain of 12 holders — while 29 added to existing stakes and 16 trimmed.
The largest buyer was OrbiMed, adding an estimated $3.6M. The largest seller was EverPoint Asset Management, cutting an estimated $437K.
- 78 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2016, up from 66 in Q2 2016.
- Funds reported $207M of Rocket Pharmaceuticals stock for Q3 2016, up 41% quarter-over-quarter.
- 17 funds opened new Rocket Pharmaceuticals positions in Q3 2016 and 5 closed out, a net change of +12 holders.
- The largest Rocket Pharmaceuticals buyer in Q3 2016 was OrbiMed, an estimated $3.6M added.
- The largest Rocket Pharmaceuticals seller in Q3 2016 was EverPoint Asset Management, an estimated $437K sold.
Based on aggregated 13F filings for Q3 2016.